leronlimab + chemotherapy

Leronlimab + chemotherapy refers to investigational combination regimens involving **leronlimab**, a humanized IgG4 monoclonal antibody targeting the chemokine receptor **CCR5**, used together with various chemotherapy agents. Leronlimab binds CCR5, inhibiting its role in tumor metastasis, immune cell trafficking, and the tumor microenvironment. In clinical trials, it is combined with standard chemotherapy drugs such as trifluridine and tipiracil (TAS-102), bevacizumab, or carboplatin, primarily for **CCR5-positive, microsatellite stable metastatic colorectal cancer (MSS mCRC)** and **CCR5-positive metastatic triple-negative breast cancer (mTNBC)**. The combinations are investigated for enhancing overall response rate, progression-free survival, and overall survival in patients who have progressed after standard chemotherapies[1][2][3][4][5].

Other names

leronlimab + trifluridine + tipiracil + bevacizumableronlimab + carboplatin